Malnati Brain Tumor Institute
2020 CME Symposium

Saturday, May 9, 2020
Northwestern Memorial Hospital
251 E. Superior St., Chicago
8:15 a.m. - 2:30 p.m.

Malnati Brain Tumor Institute
2020 CME Symposium

KEYNOTE LECTURE
How to Make Progress in Rare Tumors
Mark Gilbert, MD
Chief, Neuro-Oncology Branch
Senior Investigator, CCR Deputy Director
National Cancer Institute

COURSE DIRECTORS
James P. Chandler, MD
Roger Stupp, MD

How Rare Brain Tumors are Diagnosed in Pathology
Craig Horbinski, MD, PhD

Multidisciplinary Approach to Spine Chordomas
Jean-Paul Wolinsky, MD

Novel Strategies for the Treatment of Cranial Chordomas
James P. Chandler, MD

Medulloblastoma: Can It Be Cured?
Roger Stupp, MD

Translating Molecular Insights into Treatments of Diffuse Intrinsic Pontine Glioma
Oren Becher, MD

Pleomorphic Xanthoastrocytomas: How Molecular Diagnostics are Guiding Therapeutics
Rimas Lukas, MD

Recent Advances in Leptomeningeal Disease
Priya Kumthekar, MD

High-Grade Meningiomas: Novel Approaches Towards Characterization and Treatment
Timothy Kruser, MD

Tumor Board Case Discussion and Q&A
2020 Malnati Brain Tumor Institute CME Symposium

Saturday, May 9, 2020 • 8:15 a.m. - 2:30 p.m. • Northwestern Memorial Hospital, Feinberg Pavilion, Pritzker Auditorium, 251 E. Huron St., Chicago

Sponsored by the Northwestern Medicine Lou and Jean Malnati Brain Tumor Institute of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital, this symposium will offer participants a unique opportunity to hear from leading experts about state-of-the-art advances in neuro-oncology. Cases will be examined from multiple perspectives, providing participants with clinical pearls for diagnosing and managing malignant brain tumors to improve patient outcomes.

LEARNING OBJECTIVES

After attending this educational activity, participants should be able to:

• Review current treatment strategies for rare tumors types including Ependymomas, Medulloblastomas, Chordomas, Diffuse Intrinsic Pontine Gliomas (DIPG), and Choroid Plexus Papillomas.
• Interpret new clinical data on experimental agenda currently under evaluation in rare brain tumors to identify opportunities to optimize treatment.
• Describe the current developments in novel therapeutic agents:
  • Integration of new targets into new therapeutics.
  • Availability of clinical trials across the country.
  • Novel surgical techniques for cranial and spinal chordomas.
  • Novel radiation techniques and modalities for the treatment of rare brain tumors.

ACCREDITATION STATEMENT

The Northwestern University Feinberg School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

The Northwestern University Feinberg School of Medicine designates this educational activity for a maximum of 4.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Nurses Credentialing Center (ANCC) and the Illinois Department of Financial and Professional Regulation accept AMA PRA Category 1 Credits™ from organizations accredited by the ACCME for relicensure & recertification requirements. 1 CME credit is equivalent to 1 contact hour. Your certificate of completion, which includes the number of CME credits awarded, is the only documentation required.

For more information and to register, visit cancer.northwestern.edu/mbti-cme

Discount registration is available for Northwestern affiliates. Registration fee includes breakfast, lunch, course materials and continuing education credit. Sponsorship opportunities are available.

SPONSORED BY

Northwestern Medicine
Feinberg School of Medicine